bioRxivCancer BiologyPreprint
Decoding the Plasma Proteomic Landscape of Clear Cell Renal Cell Carcinoma Reveals Diagnostic and Prognostic Liquid Biopsy Biomarkers
Harini LakshminarayananiD, Dorothea RutishauseriD, Peter SchramliD, Daniel EberliiD, Hella Anna BolckiD, Holger MochiD
Abstract
Clear cell renal cell carcinoma (ccRCC) remains the most lethal urological malignancy, with high metastatic rates, both at initial diagnosis and during disease progression, contributing to poor survival outcomes. Current diagnostic and prognostic approaches rely primarily on histopathology, limiting early detection of localized disease and relevant intervention for metastatic patients. Here, we performed the most extensive to-date mass spectrometry-based discovery profiling of longitudinal plasma samples collected across multiple clinical follow-up points spanning up to five years post-diagnosis., to characterize the circulating plasma proteome and identify biomarkers for localized and metastatic disease. Network analysis identified protein modules enriched in pathways involved in matrix remodeling and metabolic deregulation, perpetuating the ccRCC phenotype. A five-protein signature, comprising PRL, THBS1, ANGPT1, IGFBP1, and SRGN, demonstrated high diagnostic performance for localized ccRCC. Notably, PRL appeared as a promising stand-alone biomarker (AUC = 0.812), with independent validation confirming its utility as a diagnostic biomarker. Importantly, a six-protein signature (AMBP, C1S, C2, IGFBP3, RASGRP2, TFRC) stringently distinguished metastatic from high-grade non-metastatic ccRCC cases. Further validation of these signatures could inform clinical decision-making, enabling early detection of metastasis and minimal residual disease and real-time longitudinal monitoring for ccRCC patients. Statement of SignificanceThis study presents the most comprehensive longitudinal plasma proteomic dataset for ccRCC to date, defining robust circulating protein biomarker signatures for both localized and metastatic disease, and establishing a proteomic landscape for minimally invasive, real-time monitoring and improved clinical management of ccRCC patients. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=118 SRC="FIGDIR/small/742031v1_ufig1.gif" ALT="Figure 1000"> View larger version (35K): org.highwire.dtl.DTLVardef@196d9eorg.highwire.dtl.DTLVardef@16bbee5org.highwire.dtl.DTLVardef@c1c1a1org.highwire.dtl.DTLVardef@8f62a7_HPS_FORMAT_FIGEXP M_FIG C_FIG
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Quantitative proteomics identifies secreted diagnostic biomarkers as well as tumor-dependent prognostic targets for clear cell Renal Cell Carcinoma
A. Senturk, A. T. Sahin, … N. Ozlu·bioRxiv·Feb 8, 2021
- Urinary multi-omics reveal non-invasive diagnostic biomarkers in clear cell renal cell carcinoma
Gustav Jonsson, Tiago Oliveira, … Josef Martin Penninger·EMBO Molecular MedicinePeer-reviewed·Aug 11, 2026
- Proteomic characterization of sporadic clear cell renal cell carcinoma reveals a matrix-dense pseudocapsule and heterogeneous tumor subtypes
Tobias Feilen, Grigor Andreev, … Oliver Schilling·bioRxiv·Oct 23, 2025
- Seven blood biomarkers are associated with TGF-β and VHL-HIF signaling in patients with clear cell renal cell carcinoma
Pramod Mallikarjuna, Cemal Erdem, … Maréne Landström·Signal Transduction and Targeted TherapyPeer-reviewed·Sep 25, 2025
- Machine Learning-Enhanced Extraction of Protein Signatures of Renal Cell Carcinoma from Proteomics Data
Hongyi Liu, Zhuo Ma, … Hui Zhang·bioRxiv·Feb 17, 2025
- Comprehensive Analysis of the Expression and Prognosis for PSMBs in Clear Cell Renal Cell Carcinoma
Ning Jiang, Yulin Zhang, … Rong Li Yang·bioRxiv·May 12, 2022